Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor

Anti-tumor activity of the combination o

Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases

✍ Maria Pia Morelli; Tina Cascone; Teresa Troiani; Concetta Tuccillo; Roberto Bian 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB

## Abstract Purpose: The epidermal growth factor receptor (EGFR) autocrine pathway plays an important role in cancer cell growth. Vascular endothelial growth factor A (VEGF‐A) is a key regulator of tumor‐induced endothelial cell proliferation and vascular permeability. ZD6474 is an orally available